Cancer: Biotech NovaGray rolls out its radiotherapy tolerance test
Montpellier-based startup NovaGray aims to revolutionize cancer treatment using radiotherapy with a predictive radiation sensitivity test. A strategic partnership paves the way for large-scale industrialization.
Radiotherapy relies on the use of a variety of rays that target and damage tumors, gradually destroying them. It is particularly favored in the treatment of the nearly 3.5 million people suffering from prostate or breast cancer in Europe and the United States, according to a study conducted by Rothschild for the Montpellier-based biotech company NovaGray. A spin-off from the Montpellier Cancer Institute (ICM), NovaGray has developed a test that measures the tolerance to radiotherapy of patients treated for breast or prostate cancer. Based on a dual biological and algorithmic analysis, and achievable in the laboratory thanks to an automated SaaS model, this blood test aims to anticipate the risks of complications due to the side effects of radiotherapy (fibrosis and tissue necrosis for breast cancer, rectal bleeding or forms of incontinence for prostate cancer) and to optimize treatments.
